Caliper to Present Key Findings on Applications of Multispectral Imaging and Pattern Recognition Technology at ASCO 2011 Annual Meeting
Results Demonstrate Feasibility of Automated, Digital Workflow to Assist Visual Analysis of Tumor Samples Susceptible to Human Error
HOPKINTON, Mass., June 6, 2011 /PRNewswire/ — Caliper Life Sciences, Inc. (NASDAQ: CALP), a leading provider of tools and services for drug discovery and life sciences research, today announced the presentation of key findings that validate an automated, digital pathology workflow for faster and more accurate characterization and analysis of tumor samples, during the American Society of Clinical Oncology 2011 Annual Meeting in Chicago, IL.
Results demonstrate proof-of-concept for the application of Caliper's Vectra® multispectral imaging system and the inForm™ pattern recognition-based image analysis software to help automate challenging visual assessments in pathology. In the study, these technologies were utilized to count and determine the density of tumor-infiltrating lymphocytes (TILs) in ovarian cancer. The results generated by the digital pathology system were compared with those achieved through manual analysis, revealing that the semi-automated workflow showed a TIL score that correlated strongly with manual assessments, demonstrating that TIL assessments can be made practical for routine use. While this study was conducted using ovarian tumor samples, the automated workflow has applications in other cancer types, including melanoma and pancreatic.
"TIL counting has been shown to be prognostic and predictive of therapeutic response; however, it is not used today because it is too difficult to do visually or manually," said Kevin Hrusovsky, President and CEO of Caliper. "This approach has immediate applications for cancer research and clinical trial design. Ultimately, this technology may be integrated into the clinical workflow by helping pathologists accurately and efficiently identify and measure specific biomarkers, which can be used to determine personalized treatment regimens for patients."
While researchers can utilize this workflow to study the tumor microenvironment and/or stratify patients in clinical trials, results also demonstrate that Caliper's multispectral imaging and pattern recognition technology can also provide pathologists with an enabling tool that augments their ability to evaluate tumors and nodal status beyond the standard, manual staging techniques.
Caliper, Vectra, and inForm are trademarks of Caliper Life Sciences, Inc.
About Caliper Life Sciences
Caliper is a premier provider of cutting-edge technologies enabling researchers in the life sciences industry to create life-saving and enhancing medicines and diagnostic tests more quickly and efficiently. Caliper is aggressively innovating new technology to bridge the gap between in vitro assays and in vivo results, enabling the translation of those results into cures for human disease. Caliper's portfolio of offerings includes state-of-the-art microfluidics, lab automation and liquid handling, optical imaging technologies, and discovery and development outsourcing solutions. For more information please visitwww.caliperLS.com.
SOURCE Caliper Life Sciences, Inc.